Version May 2024
Imaging: Intrauterine infusion: Initial: 2 to 3 mL; may repeat in 2 to 3 mL increments as needed to achieve visualization of the fallopian tubes; maximum total dose: 10 mL.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined:
Cardiovascular: Vasodepressor syncope
Central nervous system: Dizziness
Gastrointestinal: Abdominal pain, nausea
Genitourinary: Pelvic pain, spotting
Postmarketing: Pelvic inflammatory disease, salpingitis
Pregnancy; known or suspected lower genital tract inflammation or infection; gynecologic procedure within the last 30 days; vaginal bleeding; known or suspected reproductive tract neoplasia.
Concerns related to adverse effects:
• Infection: Post-procedure gynecologic infections (eg, pelvic inflammatory disease, salpingitis, tubo-ovarian abscess) have been reported. Use is contraindicated in known or suspected genital tract infections (even if receiving antimicrobial therapy) and within 30 days of a gynecologic procedure.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Foam, Intrauterine:
ExEm: 10 mL (10 mL)
No
Foam (ExEm Intrauterine)
10 mL (per mL): $87.60
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Intrauterine: For intrauterine infusion. Administer through a 5-French or larger catheter with luer connection. Infuse 1 mL of foam to confirm proper placement of the catheter tip in the cervix and access to the uterine cavity. Use a larger catheter if there is resistance with infusion; do not force. Slowly infuse in 2 to 3 mL increments to avoid patient discomfort. Discard unused portion.
Imaging: Contrast agent indicated for sonohysterosalpingography to assess fallopian tube patency in women with known or suspected infertility.
The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.
None known.
There are no known significant interactions.
Air polymer-type A is used in the evaluation of infertility. Patients should be in the preovulatory phase of their menstrual cycle (cycle days 6 through 11) prior to use. A negative pregnancy test is required within 24 hours prior to administration.
Use is contraindicated during pregnancy due to the potential harm from the intrauterine procedure.
Air polymer-type A is used in the evaluation of infertility. Patients should be in the preovulatory phase of their menstrual cycle (cycle days 6 through 11) prior to use. A negative pregnancy test is required within 24 hours prior to administration.
It is not known if the components of air polymer-type A (hydroxyethyl cellulose, glycerin, and purified water) are present in breast milk.
However, endogenous levels of maternal glycerol are not affected following use and hydroxyethyl cellulose is poorly absorbed; adverse effects to a breastfeeding infant would not be expected. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.
Signs and symptoms of infection; pregnancy
Reconstituted air polymer-type A foam creates a contrast agent that appears echogenic within the fallopian tubes and peritoneal cavity when visualized with ultrasound.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
